SPDR Kensho Final Frontiers ETF vs Tilray Brands Inc — how do they compare? SPDR Kensho Final Frontiers ETF trades at $106.56, while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: SPDR Kensho Final Frontiers ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| ROKT | TLRY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $136.68 | $21.00 |
52-Week Low | $71.62 | $3.88 |
Market Cap | — | $591.60M |
Enterprise Value | — | $758.73M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →